Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in Israel Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in Israel News, Nityr Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in Israel By Web_Admin|2021-05-17T18:52:30+01:00October 19th, 2020|News, Nityr| Read More
Cycle Pharmaceuticals’ Supply Chain update Cycle Pharmaceuticals’ Supply Chain update News, Resource Cycle Pharmaceuticals’ Supply Chain update By Web_Admin|2021-05-17T18:52:31+01:00March 13th, 2020|News, Resource| Read More
Cycle Pharmaceuticals’ NITYR (nitisinone) tablets receives marketing authorization in Chile Cycle Pharmaceuticals’ NITYR (nitisinone) tablets receives marketing authorization in Chile News, Nityr Cycle Pharmaceuticals’ NITYR (nitisinone) tablets receives marketing authorization in Chile By Web_Admin|2021-05-17T18:52:31+01:00November 22nd, 2018|News, Nityr| Read More
Cycle Pharmaceuticals Receives FDA Approval and Launches Ketorolac Tromethamine Injection 30mg/mL in the U.S. Cycle Pharmaceuticals Receives FDA Approval and Launches Ketorolac Tromethamine Injection 30mg/mL in the U.S. Generics, News Cycle Pharmaceuticals Receives FDA Approval and Launches Ketorolac Tromethamine Injection 30mg/mL in the U.S. By Web_Admin|2021-05-17T18:52:31+01:00August 29th, 2018|Generics, News| Read More
Cycle Pharmaceuticals Receives FDA Approval for Ketorolac Tromethamine Tablets in the U.S. Cycle Pharmaceuticals Receives FDA Approval for Ketorolac Tromethamine Tablets in the U.S. Generics, News Cycle Pharmaceuticals Receives FDA Approval for Ketorolac Tromethamine Tablets in the U.S. By Web_Admin|2021-05-17T18:52:31+01:00August 29th, 2018|Generics, News| Read More
Cycle Pharmaceuticals launches free trial of NITYR in the US and Partners with Cambrooke Therapeutics to Support HT-1 Patients’ dietary needs Cycle Pharmaceuticals launches free trial of NITYR in the US and Partners with Cambrooke Therapeutics to Support HT-1 Patients’ dietary needs News, Nityr Cycle Pharmaceuticals launches free trial of NITYR in the US and Partners with Cambrooke Therapeutics to Support HT-1 Patients’ dietary needs By Web_Admin|2021-05-17T18:52:31+01:00November 10th, 2017|News, Nityr| Read More
First recommendation for HT-1 treatment in Quebec by INESSS First recommendation for HT-1 treatment in Quebec by INESSS News First recommendation for HT-1 treatment in Quebec by INESSS By Web_Admin|2021-05-17T18:52:31+01:00June 2nd, 2017|News| Read More
CYCLE Pharmaceuticals, The University of Cambridge and King’s College London Partner to Repurpose PARP Inhibitor Drugs for Vascular Disease CYCLE Pharmaceuticals, The University of Cambridge and King’s College London Partner to Repurpose PARP Inhibitor Drugs for Vascular Disease News CYCLE Pharmaceuticals, The University of Cambridge and King’s College London Partner to Repurpose PARP Inhibitor Drugs for Vascular Disease By Web_Admin|2021-05-17T18:52:31+01:00December 19th, 2016|News| Read More
CYCLE Pharmaceuticals Nitisinone Tablets Approved by Health Canada for the Treatment of HT-1 CYCLE Pharmaceuticals Nitisinone Tablets Approved by Health Canada for the Treatment of HT-1 News CYCLE Pharmaceuticals Nitisinone Tablets Approved by Health Canada for the Treatment of HT-1 By Web_Admin|2021-05-17T18:52:31+01:00November 8th, 2016|News| Read More
